Join us for an exclusive masterclass designed for innovators and entrepreneurs in the health tech sector. This session is dedicated to helping you validate your idea with peers and experts and take your entrepreneurial skills to the next level.

This masterclass is specifically designed for health tech innovators eager to elevate their ideas through effective commercialisation. Shifting the focus towards the foundational steps of scaling your idea, this session zeroes in on the art of customer discovery to validate your concept thoroughly.

During this masterclass, participants will learn:

Strategies for identifying, defining, and segmenting key stakeholders: customers, payers, and decision-makers.
Techniques for uncovering and analysing market opportunities, including how to distinguish between primary and secondary markets.
A systematic approach to validating your idea within the market.
Fundamentals of conducting interviews, covering etiquette, techniques, ethics, crafting impactful questions, and generating useful data.
Best practices in communication and stakeholder management to ensure your idea resonates and gains traction

Meet the Experts:

Who Should Attend:
This masterclass is ideal for start-up founders, researchers, CEOs, and team members of health tech ventures.

**Lunch will be provided

Cicada Innovations is proud to be collaborating with the Westmead Health & Innovation District, Australia’s fastest-growing health and innovation precinct, for this commercialisation masterclass series. These masterclasses are to help bridge the gap between research and commercialisation.

Find out more about the Cicada HealthTech Hub

The Cicada HealthTech Hub is proudly supported by NSW Government and is part of the Westmead’s Health & Innovation District. The district includes 4 major hospitals, 4 world-leading medical research institutes, 2 university campuses and the largest research-intensive pathology service in NSW. By 2036, the number of full-time staff will increase to more than 50,000 and the number of students will expand to more than 10,000. Among the first projects for development is a viral vector advanced manufacturing facility to provide ground-breaking trial therapies for infections, cancer and genetic diseases.